Cell surface amyloid beta-protein precursor colocalizes with beta 1 integrins at substrate contact sites in neural cells.

Department of Neurology, Harvard Medical School, Boston, Massachusetts 02115, USA.
The Journal of Neuroscience : The Official Journal of the Society for Neuroscience (Impact Factor: 6.75). 03/1997; 17(3):1004-10.
Source: PubMed

ABSTRACT Amyloid beta-protein (A beta), the principal constituent of the senile plaques seen in Alzheimer's disease (AD), is derived by proteolysis from the beta-amyloid precursor protein (beta PP). The distribution and trafficking of cell surface beta PP are of particular interest because some of these molecules are direct precursors of secreted A beta and because the localization of beta PP at the cell surface may be related directly to its physiological functions. Recently, we reported that, in cultured hippocampal neurons, cell surface beta PP is preferentially expressed on axons in a striking discontinuous pattern. In this study, we describe the colocalization of cell surface beta PP and integrins in primary cultured cells. In rat hippocampal neurons, cell surface beta PP was colocalized selectively with alpha 1 beta 1 and alpha 5 beta 1 integrin heterodimers at these characteristic segmental locations. In rat cortical astrocytes, both cell surface beta PP and beta 1 integrin were located at the cell periphery in the "spreading" stage shortly after plating. In "flattened" astrocytes cultured for several days, beta PP was found in punctate deposits called point contacts. In these sites, beta PP was colocalized with alpha 1 beta 1, but not with alpha 5 beta 1 integrin heterodimers, the latter of which were situated at focal contact sites. In both neurons and astrocytes examined after shearing, clathrin and alpha-adaptin were colocalized with beta PP on the surface that directly contacts the substratum. These results are consistent with the putative role of beta PP in cell adhesion and suggests that beta PP either interacts with selected integrins or shares similar cellular machinery to promote cell adhesion.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Previous studies show that transient axonal glycoprotein-1, a ligand of amyloid precursor protein, increases the secretion of amyloid precursor protein intracellular domain and is involved in apoptosis in Alzheimer's disease. In this study, we examined the effects of transient axonal glycoprotein-1 on U251 glioma cells. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay showed that transient axonal glycoprotein-1 did not inhibit the proliferation of U251 cells, but promoted cell viability. The terminal deoxynucleotidyl transferase dUTP nick end labeling assay showed that transient axonal glycoprotein-1 did not induce U251 cell apoptosis. Real-time PCR revealed that transient axonal glycoprotein-1 substantially upregulated levels of amyloid precursor protein intracellular C-terminal domain, and p53 and epidermal growth factor receptor mRNA expression. Thus, transient axonal glycoprotein-1 increased apoptosis-related gene expression in U251 cells without inducing apoptosis. Instead, transient axonal glycoprotein-1 promoted the proliferation of these glioma cells.
    Neural Regeneration Research 03/2014; 9(5):519-25. DOI:10.4103/1673-5374.130079 · 0.23 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The hallmark pathologic lesions of Alzheimer's disease (AD) are extracellular senile plaques, composed by Amiloid (A) peptide and intraneuronal neurofibrillary tangles, made of tau protein. According to the amyloid hypothe-sis, the increased production or decreased clearance of A peptide initiates a pathological process leading to neurodegen-eration, dementia and death. Under normal circumstances, the Amyloid Precursor Protein (APP) is cleaved by secretase, but, in pathological conditions, it is cleaved first by secretase (BACE) and subsequently by -secretase, to form A42 toxic peptide. Accumulation of A42 starts a cascade of events associated with neuronal and synaptic dys-function, inflammatory responses, hyperphosphorylation of tau protein and neuronal death. This theory identifies biologi-cal targets for disease-modifying treatments, including the modulation of APP metabolism, the reduction of A aggrega-tion or the enhancement of A clearance, and the reduction of inflammation. Regarding secretases, different approaches are under evaluation, primarily aiming to decrease -and -secretase. A promising approach is the modulation of A, with either vaccination or antiaggregation agents. Regarding inflammation, despite trials with Rofecoxib, Naproxen or Di-clofenac failed to slow progression of cognitive decline in patients with AD, Indomethacin showed positive results in de-laying cognitive decline. However, gastrointestinal toxicity was treatment-limiting, therefore other compounds have been developed, including Nitroflurbiprofen. In addition, Rosiglitazone, an oral anti-diabetic agent with anti-inflammatory properties, is currently in phase III study. A further approach aims to inhibit tau deposition with methyl thioninium chloride. In this review, the pathogenic steps leading to neurodegeneration will be discussed, together with an update of disease-modifying drugs under testing.
    The Open Geriatric Medicine Journal 12/2008; 1(1):33-42. DOI:10.2174/1874827900801010033
  • Source